Prothena Announces Proposed Offering of Ordinary Shares
(Thomson Reuters ONE) -
DUBLIN, Ireland, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
today announced that it has commenced an underwritten public offering of
2,250,000 of its ordinary shares. All of the ordinary shares in the offering
will be sold by Prothena. In addition, Prothena has granted the underwriters a
30-day option to purchase up to an additional 337,500 of its ordinary shares.
RBC Capital Markets, UBS Investment Bank and Barclays are acting as joint book-
running managers. The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering will be completed, or as to the
actual size or terms of the offering.
The ordinary shares of Prothena described above are being offered only by means
of a prospectus supplement and base prospectus forming part of an effective
shelf registration statement filed with the Securities and Exchange Commission.
Copies of the prospectus for this offering may be obtained, when available, by
contacting RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY
10281-8098; Attention: Equity Syndicate; Tel: (877) 822-4089;
email: equityprospectus(at)rbccm.com; UBS Securities LLC, 1285 Avenue of the
Americas, New York, New York 10019; Attention Prospectus Department; Tel: (888)
827-7275 or from Barclays Capital Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847,
or by email at Barclaysprospectus(at)broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or other jurisdiction.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused
on the discovery, development and commercialization of novel protein
immunotherapies for the potential treatment of diseases that involve amyloid or
cell adhesion. The Company is developing antibody-based product candidates that
target a number of potential indications including AL amyloidosis (NEOD001),
Parkinson's disease and other related synucleinopathies (PRX002) and psoriasis
and other inflammatory diseases (PRX003).
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate
to, among other things, the timing and size of the proposed offering, the
conditions affecting the capital markets, general economic, industry, or
political conditions, and the satisfaction of customary closing conditions
related to the proposed offering. These statements are based on estimates,
projections and assumptions that may prove not to be accurate, and actual
results could differ materially from those anticipated due to known and unknown
risks, uncertainties and other factors, including but not limited to the risks,
uncertainties and other factors described in the "Risk Factors" sections of
Prothena's Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission (SEC) on November 2, 2015 and in the preliminary prospectus
supplement related to the proposed offering to be filed with the SEC on or about
the date hereof. Prothena undertakes no obligation to update publicly any
forward-looking statements contained in this press release as a result of new
information, future events or changes in Prothena's expectations.
Contact
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
[HUG#1976885]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Destiny Media Technologies Schedules First Quarter Fiscal 2016 Earnings Release and Conference Call
Datum: 05.01.2016 - 22:01 Uhr
Sprache: Deutsch
News-ID 442568
Anzahl Zeichen: 4768
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Announces Proposed Offering of Ordinary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
